Stay updated with breaking news from Pascal Deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Needham & Company LLC reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $60.00 price objective on the stock. A number of other analysts have also commented on APLS. Oppenheimer reissued an outperform rating on shares […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) insider Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $23.66, for a total value of $283,920.00. Following the completion of the sale, the insider now owns 1,053,313 shares of the […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective reduced by Raymond James from $156.00 to $89.00 in a research note issued to investors on Tuesday, Benzinga reports. Raymond James currently has a strong-buy rating on the stock. Other equities analysts have also issued research reports about the stock. Citigroup dropped their price target […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) released its earnings results on Monday. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.33, MarketWatch Earnings reports. Apellis Pharmaceuticals had a negative return on equity of 221.60% and a negative net margin of 356.02%. The business had revenue of $95.00 […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $25.88 and last traded at $25.95, with a volume of 8073849 shares trading hands. The stock had previously closed at $32.02. Analysts Set New Price Targets Several equities research […]